Protein profiling in pathology: Analysis and evaluation of 239 frozen tissue biopsies for diagnosis of B‐cell lymphomas

Abstract

SELDI-TOF MS protein profiling allows for reliable identification of the majority of malignant lymphoma cases; however, further validation and testing robustness in a diagnostic setting is needed.

Potential role of proteomics in the diagnosis of lymphoma: a meta‐analysis

“…Four [26][27][28][29] included kinds of stages and subtypes of lymphoma. One [20] focused on B-cell lymphomas. The remaining three papers were related to Coetaneous T-cell lymphomas (CTCL) [30], mycosis fungoides (MF) [19] and diffuse large-B-cell lymphoma (DLBCL) [31], respectively.…”

“…Seven studies clearly pointed out that treatment was withheld until both the index test and reference standard were performed except Jiang [28], Cheng [27], Escher [30] and Escher [19], which were not available. Four studies, Jiang [28], Chen [25], Jansen [20] and Zhang [24], were prespecified objectively, and remains were not available.…”

“…Data extraction was the key point of systematic review, accordingly, every paper should obtain some quantification parameters such as numbers of testing set/group, sensitivity and specificity, with which we could construct a 2 9 2 table (Table 3). In Table 3, some authors built different molecule phenotype models [30], and some researchers applied various algorithms like artificial neural network (ANN) or Biomarker Patterns Software (BPS) to establish models [20,28]. All of these could affect different diagnosis values, so authors drew the data from the same studies as a new group in 2 9 2 table.…”

“…Meanwhile, Jansen et al [20] discussed that both the classification and regression tree and logistic regression classification correctly identified the majority of the B-cell lymphoma (87% and 96%, respectively) and benign cases (73% and 75%, respectively) with SELDI. Because a number of manuscripts have reported varying results about diagnostic values of the method for identifying lymphoma, the study undertook a systematic review to assess the overall accuracy of the technique.…”

New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010–January 2011

“…It is a more difficult to standardize compared with DNA and even RNA approaches. Jansen et al [53] determined the potential value of protein profiling of tissue samples by assessing how precise this approach enables discrimination of B cell lymphoma from reactive lymph nodes and how well the profiles can be used for lymphoma classification. Protein lysates from lymph nodes (n=239) from patients with the diagnosis of reactive hyperplasia (n=44), FL (n=63), DLBL (n=43), MCL (n=47), and CLL (n=42) were analyzed by SELDI-TOF MS.…”